Horizon Investment Services LLC Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Horizon Investment Services LLC grew its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 167.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 39,524 shares of the biopharmaceutical company’s stock after acquiring an additional 24,724 shares during the quarter. Horizon Investment Services LLC’s holdings in Catalyst Pharmaceuticals were worth $825,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CPRX. Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth $27,000. Farther Finance Advisors LLC raised its stake in Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 1,495 shares in the last quarter. Larson Financial Group LLC lifted its holdings in Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter worth about $65,000. Finally, KBC Group NV boosted its position in Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,542 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CPRX. Robert W. Baird raised their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Finally, Stephens reaffirmed an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $32.29.

Catalyst Pharmaceuticals Stock Down 0.6 %

NASDAQ:CPRX opened at $24.69 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of 20.92, a PEG ratio of 3.31 and a beta of 0.84. The company’s 50 day moving average price is $22.66 and its 200-day moving average price is $21.80.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.